AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations • New York
ORDERED that judgment on priority as to Count 1 (the sole count in the interference: Paper 1, pages 6-7) is awarded against Junior Party Kontermann.
LICENSE AGREEMENTLicense Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”), effective as of September 29, 2006 (the “Effective Date”), is entered into by and between XOMA Ireland Limited, a company with limited liability organized under the laws of the Republic of Ireland having offices at Shannon Airport House, Shannon, County Clare, Ireland (with its Affiliates, “XOMA”), and Affimed Therapeutics AG, a company organized under the laws of the Federal Republic of Germany, with offices at Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (with its Affiliates, “AFFIMED”).
AMENDMENT NO. 1 to the RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
This Amendment (the “Amendment”) is made as of April 29th, 2014 (the “Amendment Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are hereinafter referred to individually as the “Party” and together as the “Parties”.
LEASE CONTRACTLease Contract • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
In this event, the Contracting Parties agree that the period of notice shall be 3 months and it shall begin to run on the first day of the month after the delivery of the written notice of termination to the Tenant.
Amendment No. 5 to Lease Contract dated 1.10. 2009 entered into by and between the following Contractual Parties on the day, month and year specified below:Affimed Therapeutics B.V. • June 27th, 2014 • Pharmaceutical preparations
RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations • New York
This Agreement (the “Agreement”) is made as of August 26th, 2013 (the “Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
Amendment No. 4 to Lease Contract dated 1.10. 2009 entered into by and between the following Contractual Parties on the day, month and year specified below:Affimed Therapeutics B.V. • June 27th, 2014 • Pharmaceutical preparations
furthermore two (2) parking spaces designated as PA 50 and PA 54, each with an area of approximately 12 m², located on land No. 1538/12 in the cadastral area of Skvrňany, Pilsen municipality,
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.Affimed Therapeutics B.V. • June 27th, 2014 • Pharmaceutical preparations
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
